New Developments in the Use of Atypical Antipsychotics in the Treatment of Bipolar Disorder: a Systematic Review of Recent Randomized Controlled Trials.
Kamyar KeramatianTrisha ChakrabartyGayatri SarafLakshmi N YathamPublished in: Current psychiatry reports (2021)
Several studies supported efficacy of quetiapine monotherapy in acute bipolar I (BDI) and bipolar II (BDII) depression. Moreover, quetiapine adjunctive therapy showed superior efficacy to placebo in treatment-resistant bipolar depression. Cariprazine 1.5 mg was effective in treating bipolar I depression. Aripiprazole 400 mg IM once monthly was effective in preventing manic episodes with minimal metabolic effects. In youth with BD, lurasidone was effective and well-tolerated for acute depression while asenapine showed efficacy in treating acute manic and mixed episodes. Recently published RCTs generally support the efficacy of atypical antipsychotics in different phases of BD. Future studies should focus on understudied populations including pediatric BD and geriatric BD and BDII, as well as a focus on cognitive functioning and quality of life measures.
Keyphrases
- bipolar disorder
- major depressive disorder
- liver failure
- depressive symptoms
- sleep quality
- respiratory failure
- randomized controlled trial
- drug induced
- aortic dissection
- physical activity
- mental health
- clinical trial
- open label
- mesenchymal stem cells
- stem cells
- hepatitis b virus
- intensive care unit
- bone marrow
- extracorporeal membrane oxygenation
- mechanical ventilation
- acute respiratory distress syndrome
- double blind
- meta analyses